ReviewWorld journal of gastrointestinal surgery2025
Pancreatogenic diabetes: Pathophysiology, diagnosis, and management challenges.
Review in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resveratrol in diabetes and pancreatic function: implications for the exocrine-endocrine pancreatic axis-a systematic review.Frontiers in nutrition · 2026Pooled it
- Estimation of Resting Energy Expenditure in Patients Undergoing Total or Partial Pancreatectomy for Pancreatic Tumors.Nutrients · 2026Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatogenic diabetes, also known as type 3c diabetes, arises from pancreatic dysfunction due to conditions such as chronic pancreatitis and pancreatic cancer. This form of diabetes is characterized by both endocrine and exocrine pancreatic insufficiency, leading to insulin deficiency, glycemic variability, and maldigestion. The diagnostic process remains complex, as it shares clinical features with type 2 diabetes, and there are no standardized diagnostic criteria. Current treatment approaches include insulin therapy and pancreatic enzyme replacement therapy, along with nutritional support. However, the efficacy of oral hypoglycemic agents is limited, particularly in the presence of exocrine insufficiency. Epidemiological data indicate a significant overlap between pancreatogenic diabetes and pancreatic cancer, necessitating enhanced screening in high-risk populations. In this minireview, we highlight the pathophysiological mechanisms, diagnostic challenges, and current management strategies, emphasizing the need for improved diagnostic criteria and individualized treatment regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.